Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Arvinas Holding Company ( (ARVN) ).
On September 17, 2025, Arvinas announced a 15% workforce reduction primarily affecting roles related to the commercialization of vepdegestrant, expecting to incur $4.5 million in related costs. The company also updated its collaboration with Pfizer, agreeing to out-license vepdegestrant’s commercialization rights to a third party, aiming to optimize costs and streamline operations. Additionally, Arvinas introduced a $100 million share repurchase program, reflecting confidence in its business strength and commitment to maximizing shareholder value. These strategic actions are expected to save over $100 million annually compared to FY 2024 and extend the company’s cash runway into the second half of 2028.
The most recent analyst rating on (ARVN) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
Arvinas’ overall score is primarily impacted by its financial challenges, including persistent losses and declining revenue. While there are positive developments in clinical trials and strategic initiatives, these are offset by revenue decline and restructuring costs. Technical indicators suggest a neutral trend, but valuation remains unattractive due to ongoing losses.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Arvinas, Inc. is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC (PROteolysis TArgeting Chimera) platform. The company aims to treat debilitating and life-threatening diseases by selectively degrading disease-causing proteins. Arvinas is advancing multiple investigational drugs, including vepdegestrant for breast cancer, ARV-393 for non-Hodgkin lymphoma, ARV-102 for neurodegenerative disorders, and ARV-806 for mutated cancers.
Average Trading Volume: 1,809,192
Technical Sentiment Signal: Sell
Current Market Cap: $568.3M
See more data about ARVN stock on TipRanks’ Stock Analysis page.